Fig. 1
From: Knockout of endothelin type B receptor signaling attenuates bleomycin-induced skin sclerosis in mice
Study design and body-weight changes of each mice group after BLM treatment. a Summary of this experimental model and sample number of each group. Osmotic pumps containing 200 μl of BLM (125 mg/kg) or PBS were implanted subcutaneously onto the back of WT or ETBKO mice on day 0. Pumps deliver their contents 1.0 μg/h for 7 days. Mice were sacrificed on day28. b Body-weight changes from day 0 to day 28 in WT and ETBKO mice. The body-weight change was calculated as [(body weight on day 28) − (body weight on day 0)] × (body weight on day 0)-1 × 100 (%). Each dot indicates the body-weight change in an individual mouse (* p < 0.05). BLM bleomycin, DβH-ET B endothelin type B receptor transgene driven by the human dopamine β-hydroxylase gene promoter, ET B KO endothelin type B receptor knockout, PBS phosphate-buffered saline, WT wild-type